228 related articles for article (PubMed ID: 23681745)
1. ERBB4 confers metastatic capacity in Ewing sarcoma.
Mendoza-Naranjo A; El-Naggar A; Wai DH; Mistry P; Lazic N; Ayala FR; da Cunha IW; Rodriguez-Viciana P; Cheng H; Tavares Guerreiro Fregnani JH; Reynolds P; Arceci RJ; Nicholson A; Triche TJ; Soares FA; Flanagan AM; Wang YZ; Strauss SJ; Sorensen PH
EMBO Mol Med; 2013 Jul; 5(7):1087-102. PubMed ID: 23681745
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.
Kang HG; Jenabi JM; Zhang J; Keshelava N; Shimada H; May WA; Ng T; Reynolds CP; Triche TJ; Sorensen PH
Cancer Res; 2007 Apr; 67(7):3094-105. PubMed ID: 17409416
[TBL] [Abstract][Full Text] [Related]
3. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
4. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
Satterfield L; Shuck R; Kurenbekova L; Allen-Rhoades W; Edwards D; Huang S; Rajapakshe K; Coarfa C; Donehower LA; Yustein JT
Int J Cancer; 2017 Nov; 141(10):2062-2075. PubMed ID: 28748534
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.
Potratz J; Tillmanns A; Berning P; Korsching E; Schaefer C; Lechtape B; Schleithoff C; Unland R; Schäfer KL; Müller-Tidow C; Jürgens H; Dirksen U
Mol Oncol; 2016 May; 10(5):677-92. PubMed ID: 26739507
[TBL] [Abstract][Full Text] [Related]
7. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
Moore C; Parrish JK; Jedlicka P
PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
[TBL] [Abstract][Full Text] [Related]
8. Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.
Krook MA; Nicholls LA; Scannell CA; Chugh R; Thomas DG; Lawlor ER
Mol Cancer Res; 2014 Jun; 12(6):953-64. PubMed ID: 24651452
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
10. hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.
Passacantilli I; Frisone P; De Paola E; Fidaleo M; Paronetto MP
Nucleic Acids Res; 2017 Dec; 45(21):12270-12284. PubMed ID: 29036465
[TBL] [Abstract][Full Text] [Related]
11. A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway.
Yang Y; Ma Y; Gao H; Peng T; Shi H; Tang Y; Li H; Chen L; Hu K; Han A
Oncogene; 2021 Jan; 40(4):731-745. PubMed ID: 33239755
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
13. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
[TBL] [Abstract][Full Text] [Related]
14. High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.
Hong SH; Tilan JU; Galli S; Izycka-Swieszewska E; Polk T; Horton M; Mahajan A; Christian D; Jenkins S; Acree R; Connors K; Ledo P; Lu C; Lee YC; Rodriguez O; Toretsky JA; Albanese C; Kitlinska J
Oncotarget; 2015 Mar; 6(9):7151-65. PubMed ID: 25714031
[TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.
Kamura S; Matsumoto Y; Fukushi JI; Fujiwara T; Iida K; Okada Y; Iwamoto Y
Br J Cancer; 2010 Jul; 103(3):370-81. PubMed ID: 20606682
[TBL] [Abstract][Full Text] [Related]
16. miR-124 represses the mesenchymal features and suppresses metastasis in Ewing sarcoma.
Li Y; Shao G; Zhang M; Zhu F; Zhao B; He C; Zhang Z
Oncotarget; 2017 Feb; 8(6):10274-10286. PubMed ID: 28055964
[TBL] [Abstract][Full Text] [Related]
17. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.
Choo S; Wang P; Newbury R; Roberts W; Yang J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28873262
[TBL] [Abstract][Full Text] [Related]
20. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A; Joerschke M; Shinde DA; Braunschweig T; Meier A; Makowska A; Bortnick R; Henneke P; Herget G; Gorr TA; Kontny U
BMC Cancer; 2015 Jul; 15():552. PubMed ID: 26215971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
